Dr. Zhiwei Hu is a Research Scientist (Research Associate Professor) in the Dept of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. Dr. Hu is one of first few scientists who proposed to target both the tumor cells and tumor neovasculature for development of novel dual neovascular- and cancer cell-targeted therapy for cancer. As co-inventor he holds 4 US patents of Icon and its uses. The Icon that Dr. Hu co-invented has been tested for immunotherapy of cancer, aged-related macular degeneration (AMD) and endometriosis in preclinical studies as well as in Phase I clinical trial (for AMD patients). Recently his laboratory developed another targeted therapeutics, namely factor VII (fVII)-targeted photodynamic therapy (PDT) using fVII peptides-conjugated photosensitizers for cancer (including chemoresistant breast cancer) and AMD. He is member of the Yale Cancer Center, American Association for Cancer Research, and The American Association of Immunologists. He is an Adjunct Professor of Sichuan University School of Medicine and Nanchang University School of Medicine in China, and a Scientific Advisor for Iconic Therapeutics Inc. In 2011 he was elected as Vice President of the Chinese Association for Science and Technology in Connecticut (CAST-CT). He is a peer reviewer for numerous scientific journals in immunology, photodynamic therapy and cancer research and serves as an editor or editorial (review)/board member of The Journal of Immune Based Therapies, Vaccines and Antimicrobials, The Journal of Analytical & Bioanalytical Techniques, The Journal of Solid Tumors, Advances in Breast Cancer Research and Open Journal of Immunology. Starting February 2012, he serves as Editor-in-Chief of The Journal of Analytical & Bioanalytical Techniques.
Biography Updated on 27 August 2012